


STATUS OF THE CLAIMS

1. (previously presented) A composition comprising a drug-eluting stent media; wherein said drug-eluting stent media comprises a pharmaceutical composition; wherein said pharmaceutical composition comprises an agent, wherein said agent is:



2-11. (canceled).

12. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media is in contact with a drug-eluting stent.

13. (previously presented) The composition of Claim 12, wherein said drug-eluting stent is seeded with endothelial cells.

14. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anticoagulant drug.

15. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an antiplatelet drug.

16. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an antimicrobial agent.

17. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anti-inflammatory agent.

18. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anti-metabolic agent.

19. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises a vasoreactive agent.

20. (previously presented) The composition of Claim 14, wherein said vasoreactive agent is a nitric oxide releasing agent.